Restricted accessResearch articleFirst published online 1996-1
Activity of Nadifloxacin against Methicillin-Resistant Staphylococcus aureus Isolated from Skin Infections: Comparative Study with Seven other Fluoroquinolones
The in vitro susceptibility of methicillin-resistant Staphylococcus aureus(MRSA) to nadifloxacin and seven other fluoroquinolones (norfloxacin, ofloxacin, enoxacin, ciprofloxacin, lomefloxacin, tosufloxacin and sparfloxacin) was evaluated. The MRSA isolates were isolated from 114 skin infections between 1991 and 1994. Nadifloxacin exhibited the lowest minimum inhibitory concentration and there were no MRSA isolates resistant to nadifloxacin, while there were some resistant to all of the other seven fluoroquinolones. The minimum concentrations of these drugs needed to cause 50% inhibition of the isolates increased dramatically from 1991 to 1992, but has hardly changed since 1992.
NishijimaSNamuraSMitsuyaK: Retrospective study of bacteria isolated from skin infections during past 15 years (1977–1991) At Kansai Medical University. Nippon Hifuka Gakkai Zasshi1993; 103: 1988–1991.
2.
AkiyamaHYamadaTSimoeK: Characteristics and susceptibilities to antimicrobial agents of Staphylococcus aureus isolates isolated in dermatology. Chemotherapy1990; 38: 9–20.
3.
NishijimaSNamuraSMitsuyaK: The incidence of isolation of methicillin-resistant Staphylococcus aureus (MRSA) strains from skin infections during the past three years (1989–1991). J Dermatol (Tokyo)1993; 20: 193–197.
4.
ShalitIBergerSAGoreaA: Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother1989; 33: 593–594.
TakahashiHShojiSKikuchiH: Changes in susceptibility of clinical isolates of Staphylococcus aureus to quinolones and other antibacterial agents from 1986 to 1993. Jpn J Chemother1995; 43: 547–550.
7.
KawabataSOhguroKMukaiF: Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 1. In vitro antibacterial activity. Chemotherapy1989; 37: 1160–1178.
8.
KurokawaIAkamatsuHNishijimaS: Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J Am Acad Dermatol1991; 25: 674–681.
9.
NishinoT.KawabataS: In vitro antibacterial activity of the new quinolones OPC-7251. Eur J Clin Microbial Infect Dis1991; Special Issue: 188–189
10.
Japan Society of Chemotherapy: Revised standardized method for determination of the minimum inhibitory concentrations in bacteria. Chemotherapy1981; 29: 76–79.
11.
NakanishiNYoshidaSWakebeH: Mechanisms of clinical resistance to fluoroquinolones inStaphylococcus aureus. Antimicrob Agents Chemother1991; 35: 2562–2567.
12.
TakahashiHShojiSKikuchiH: Rate of occurrence of mutations at Ser-84 in Staphylococcus aureus DNA gyrase A protein. Jpn J Chemother1995; 43: 515–519.
